Table 5.

Chemistry panel results indicate no adverse effects of in vivo miR-22 antagomir treatment

Chemistry panel marker	SHR treated with control (mean ± SEM)	SHR treated with antagomir (mean ± SEM)	P-value
General metabolism
Glucose (mg/dl)	189 ± 5	196 ± 3	0.23
Kidney function
BUN (mg/dl)	20 ± 1	20 ± 1	0.70
Creatinine (mg/dl)	0.2 ± 0.01	0.2 ± 0.02	0.34
Electrolytes
Sodium (mEq/l)	162 ± 1	164 ± 1	0.33
Phosphorus (mg/dl)	9.9 ± 0.2	9.5 ± 0.2	0.13
Liver function
Alkaline phosphatase (U/l)	29 ± 10	21 ± 6	0.49
Albumin (g/dl)	4.7 ± 0.1	4.7 ± 0.1	0.89
SGPT (ALT) (U/l)	68 ± 5	55 ± 2	0.02*
Total protein (g/dl)	5.8 ± 0.1	5.8 ± 0.1	0.46
Globulin (g/dl)	1.1 ± 0.1	1.1 ± 0.1	0.75
Total bilirubin (mg/dl)	0.2 ± 0.01	0.2 ± 0.02	0.34
Pancreas function
Amylase (U/l)	846 ± 17	729 ± 23	0.0008*

A standard chemistry panel was performed on plasma from SHR treated with miR-22 antagomir or negative control. Data were analyzed with Student's t-test. Statistically significant differences (P < 0.05) are indicated with *.

BUN, blood urea nitrogen; SGPT, serum glutamic pyruvic transaminase.